On 3rd August 2017, FDA approved the first-ever drug that can treat all six major strains of hepatitis C (or HCV) in just eight weeks on Thursday.
The approval of AbbVie's Mavyret is bad news for competitors like biotech giant Gilead, whose hep C treatments are an integral part of its product portfolio.
"This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients with genotype 1 infection, the most common HCV genotype in the United States, who were not successfully treated with other direct-acting antiviral treatments in the past," the FDA's Dr. Edward Cox in a statement Thursday.
No comments:
Post a Comment